Trials / Completed
CompletedNCT02468284
Pharmacokinetics of Degarelix in Chinese Patients With Prostate Cancer
An Open-label, Multi-Centre Trial Investigating Pharmacokinetics of Degarelix After a Starting Dose of 240 mg (40 mg/mL) Followed by Six Maintenance Doses of 80 mg (20 mg/mL) in Chinese Patients With Prostate Cancer Requiring Androgen Deprivation Therapy
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Ferring Pharmaceuticals · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to look at how much a new trial drug get into body, such as when the drug concentration in your body reaches peak and how high the peak value is.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | degarelix |
Timeline
- Start date
- 2015-07-01
- Primary completion
- 2016-10-13
- Completion
- 2017-10-10
- First posted
- 2015-06-10
- Last updated
- 2017-10-26
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02468284. Inclusion in this directory is not an endorsement.